Vorinostat treatment of PPS-ICBR cells

We generated immune checkpoint blockade resistant cell lines from a prostate tumor driven by Probasin-Cre Pten/P53/Smad4 loxp deletion, through serial implantation and ICB treatment. We then wanted to explore whether gene expression changes associated with resistance to immune checkpoint blockade could be reversed by treating ICB resistant cells with the pan-HDAC inhibitor Vorinostat. We used a microarray to determine gene expression changes caused by Vorinostat treatment in these cells with biological duplicates. Cells were seeded at 60% confluency and treated overnight with either DMSO or Vorinostat dissolved in DMSO. RNA was extracted and converted into cDNA and sent out for analysis.